ACM
CPRX icon

Altium Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Altium Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-255,000
Closed -$5.32M – 38
2024
Q4 		$5.32M Sell
255,000
-130,000
-34% -$2.79M 1.51% 26
2024
Q3 		$7.65M Sell
385,000
-115,000
-23% -$2.13M 2.25% 16
2024
Q2 		$7.75M Hold
500,000
– – 3.16% 12
2024
Q1 		$7.97M Buy
500,000
+115,000
+30% +$1.73M 3.15% 10
2023
Q4 		$6.47M Buy
+385,000
New +$5.26M 4.39% 7

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Altium Capital Management's CPRX Position: Q1 2025 in Review

Altium Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 255,000 shares — an estimated $5.32M sold.

Altium Capital Management first reported a position in CPRX in Q4 2023 and held it in 5 quarters. The position peaked at $7.97M in Q1 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Altium Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 255,000 Catalyst Pharmaceutical shares in Q1 2025, an estimated $5.32M.
  • Altium Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 5 quarters.
  • Altium Capital Management's Catalyst Pharmaceutical position peaked at $7.97M in Q1 2024.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.